Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma

Trial ID or NCT#

NCT00435916

Status

not recruiting iconNOT RECRUITING

Purpose

This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.

Official Title

A Phase II Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Diagnosis of DLBCL.* Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP, R-ESHAP or equivalent.* Progression or relapse since most recent therapy.* At least one measurable lesion that is both greater than or equal to 2 cm by conventional CT or greater than or equal to 1.5 cm by spiral CT.
Exclusion Criteria:
  1. * Previous diagnosis or treatment for indolent lymphoma, leptomeningeal lymphoma, or central nervous system lymphoma.* Primary refractory disease.* Received an allogenic stem cell transplant.
View All Criteria
Show Less

Investigator(s)

Sandra Horning

Contact us to find out if this trial is right for you.

Contact

Ranjana Advani
6507248372

View on ClinicalTrials.gov